Clinical trial
An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology
NCT04764669 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 25, 2021
- Completion date
- January 27, 2022
- Enrollment
- 34 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.